This Company Raised Its Earnings Guidance in May. The Stock Is Down 23% Since. Someone Is Reading This Wrong.
A growth scare is coming to this company's next earnings report. Management already announced it, in writing, three months ago — and raised profit guidance in the same breath.
There is a specific kind of setup that professional investors hunt for and almost nobody else notices.
What they’re looking for isn’t a turnaround trade or a bankruptcy fire sale, but something more subtle and more reliable: a company whose numbers are about to get worse, in a very specific way.
The smart money looks for companies whose numbers are suffering for reasons that are already public and guided. Bonus points if those reasons were even good for the business, longer term.
The market, in aggregate, is not great at holding two ideas at once. It is very good at reacting to a headline growth rate. When that headline rate is about to fall from the high twenties into the single digits, momentum money leaves before it happens. Price targets get trimmed. The chart breaks. And the whole time, the underlying earnings power is going up.
That’s exactly what’s unfolding right now inside a $10 billion medical technology company that most retail investors have never analyzed.
Here’s the shape of it.
On May 7, this company reported quarterly revenue growth of 27% and earnings per share growth of 65%. It reaffirmed its full-year revenue guidance and raised its full-year earnings guidance by roughly 7%.
Since that report, the stock is down about 23% from its 52-week high. Five different Wall Street firms have cut their price targets in the last two months.
Here’s the part that should make you sit up: almost none of them cut their rating. The consensus is still Buy. The average price target still sits roughly 35% above where the stock trades today.
When analysts slash targets but hold ratings, they are telling you something specific. They’re not saying the business is broken. They’re saying the multiple is going to compress because the optics are about to get ugly — and they don’t want to be the last one holding a Buy at a high target when it happens.
Which raises the only question that matters: is the ugliness real, or is it arithmetic?
We spent this morning pulling apart the filings, the cash flow statement, the segment disclosures, and the exact language management used in May. What we found is that the entire growth scare was pre-announced — in the guidance — on May 7. The market has spent eleven weeks selling a stock for information it already had.
And the moment of truth arrives in nine days.
The rest of this deep dive is for paid subscribers.
The full reveal, the segment math that explains why the growth rate is designed to fall, the balance sheet number that changes the risk profile entirely, the bull and bear cases, the catalyst map into the August 6 print, what the smart money is actually doing, and the one structural shift happening across this entire industry that could make this company far more valuable than its earnings suggest. Upgrade to keep reading.
